The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

Romain Donne, Amaia Lujambio – 20 August 2022 – The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy.

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation

Alix Demory, Jean‐Marie Péron, Julien Calderaro, Janick Selves, Fatima‐Zohra Mokrane, Giuliana Amaddeo, Valérie Paradis, Marianne Ziol, Olivier Sutter, Lorraine Blaise, Nathalie Ganne‐Carrié, Valérie Vilgrain, François Cauchy, Jessica Zucman‐Rossi, Maxime Ronot, Jean‐Charles Nault – 17 August 2022

Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review

Mounika Kanneganti, Jorge A. Marrero, Neehar D. Parikh, Fasiha Kanwal, Takeshi Yokoo, Mishal Mendiratta‐Lala, Nicole E. Rich, Purva Gopal, Amit G. Singal – 17 August 2022 – Patients with indeterminate liver nodules, classified as LR‐3 and LR‐4 observations per the Liver Imaging Reporting and Data System, are at risk of developing hepatocellular carcinoma (HCC), but risk estimates remain imprecise.

Outcomes of patients with acute liver failure listed for liver transplantation: A multicenter prospective cohort analysis

Constantine J. Karvellas, Thomas M. Leventhal, Jorge L. Rakela, Jingwen Zhang, Valerie Durkalski, K. Rajender Reddy, Robert J. Fontana, R. Todd Stravitz, John R. Lake, William M. Lee, Justin R. Parekh – 17 August 2022 – Liver transplantation (LT) is a life‐saving treatment for patients with acute liver failure (ALF). Currently, there are few detailed data regarding long‐term outcomes after LT for ALF.

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning – 16 August 2022

Combined liver transplantation and sleeve gastrectomy: Report of a brief‐interval staged approach

Nabil Tariq, Ashish Saharia, Ugoeze Nwokedi, Mark J. Hobeika, Constance M. Mobley, David Hsu, Lucy M. Potter, Linda W. Moore, Ahmed Elaileh, Vadim Sherman, R. Mark Ghobrial – 16 August 2022 – Pretransplantation bariatric surgery in patients with high Model for End‐Stage Liver Disease (MELD) score is fraught with risks. Bariatric surgery after liver transplantation (LT) may be complicated by surgical adhesions but could have advantages if performed at the time of transplantation. We investigated a method of brief‐interval staging combining LT and sleeve gastrectomy (SG).

Subscribe to